Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel

RMD Open. 2024 Oct 23;10(4):e004727. doi: 10.1136/rmdopen-2024-004727.

Abstract

We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.

Keywords: B-lymphocytes; arthritis, rheumatoid; autoimmune diseases; hematology; therapeutics.

Publication types

  • Case Reports

MeSH terms

  • Antigens, CD19* / immunology
  • Antigens, CD20* / immunology
  • Arthritis, Rheumatoid* / therapy
  • Female
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Immunotherapy, Adoptive* / methods
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Lymphoma, Large B-Cell, Diffuse* / therapy
  • Male
  • Middle Aged
  • Receptors, Chimeric Antigen / immunology
  • Receptors, Chimeric Antigen / therapeutic use
  • Remission Induction
  • Treatment Outcome

Substances

  • Antigens, CD19
  • Antigens, CD20
  • Receptors, Chimeric Antigen